The CDC reports that the following symptoms may appear 2-28 days after exposure:

• Coughing
• Fever
• Shortness of Breath
• Sore Throat
• Fatigue
• Body Aches
• Headches
• Diarrhea
• Abdominal Cramping

If you experienced any of these symtpoms in the last 30 days but DIDN’T receive a test for covid-19, you may want to consider the IMMUNECHECK test

• Antibodies have been found to be a highly sensitive biomarker in infections disease diagnosis, previous studies on SARS, MERS and more recently the ones on SARS-CoV2 have shown IgM antibodies to appear about the 3rd day from infection and IgG antibodies appear after 8 days.
• Profiling an individual’s antibody response is the only way to determine infections with few or no symptoms.
• Studies of the 3 subclasses of antibodies in the patient population in China showed that IgM and IgA develop first in individuals and could possibly serve as early markers. The IgG response, which is more durable, was found even 40 days after infection. 

NOTE: A patient cannot order their own tests, a doctors requisition is required for all testing. 

• Vibrand has developed a novel test for COVID-19. This test is a highly sensitive and accurate serum assay for COVID-19 viral antibodies.

  The test was internally developed and validated accourding to FDA EUA requirements. The independent review of the validation by the FDA is pending. 

• This test does not require confirmation by CDC prior to reporting results. 

IgG, IgA and IgM antibodies against the following antigens are tested:

• S1 Spike protein – The S1 subunit of the ectodomain mediates binding of the virion to host cell-surface receptors through its receptor-binding domain (RBD)
• Receptor Binding Domain – Part of the S1 Spike subunit that actually binds to the ACE2 receptor of human epithelial cell
• S2 Spike protein – The S2 subunit fuses with both host and viral membranes, by undergoing dramatic structural changes
• Nucleoprotein – Packages the positive strand viral genome RNA into a helical ribonucleocapsid (RNP) and plays a fundamental role during virion assembly through its interactions with the viral genome and membrane protein M. Plays an important role in enhancing the efficiency of subgenomic viral RNA transcription as well as viral replication.

• Qualitative chemiluminescence-based antibody detection using an array of 4 COVID-19 antigens.

• The median duration of IgM and IgA antibody detection were 5 days while IgG was detected in 14 days in most individuals. It is important to note that different individuals will produce variations of these timelines. A better idea of the immune system modulation in an individual can be gauged based on testing them twice or as appropriate to see the production of a stable IgG response.
  
  
• IgM antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although levels over the course of infection are not well characterized. IgG antibodies to SARS-CoV-2 become detectable later following infection. Positive results for both IgG and IgM could occur after infection and can be indicative of acute or recent infection.
  
  
• If a positive IgM or IgA result is detected, it is recommended to retest the patient in 10-14 days to assess whether IgG antibodies appear and whether IgM or IgA antibodies return to normal levels, signaling progression toward infection resolution or establishment of immune tolerance
  
  Reference 1: Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of Diagnostic Testing for SARS–CoV-2/COVID-19.Robin Patel, Esther Babady, Elitza S. Theel, Gregory A. Storch, Benjamin A. Pinsky, Kirsten St. George, Tara C. Smith, Stefano Bertuzzi mBio Mar 2020, 11 (2) e00722-20; DOI: 10.1128/mBio.00722-20